(CIDRAP News) – Predicting that 44% of this year's supply of influenza vaccine won't be available until November and December, federal health officials are recommending that vaccine doses available in October be reserved for healthcare workers and people who have an increased risk of influenza complications.
(CIDRAP News) The federal government is considering buying influenza vaccine from a British company in an effort to remedy a possible shortage in the United States, the head of the Centers for Disease Control and Prevention (CDC) said today.
(CIDRAP News) The new recommendation to vaccinate children between 6 and 23 months old could have been lost in the hubbub of the influenza vaccine shortage this season. Yet authorities are terming this year's vaccination rates a success story.
(CIDRAP News) Influenza vaccine doses intended for those at highest risk for serious complications from the flu made it into the arms of the right people, the Centers for Disease Control and Prevention (CDC) in Atlanta said yesterday.
(CIDRAP News) Two studies reported in today's issue of the New England Journal of Medicine provide additional support for seasonal influenza immunization while shedding some light on questions about vaccination strategies and the efficacy of the vaccines.
(CIDRAP News) – In an effort to stretch the nation's supply of vaccines for a potential influenza pandemic, federal health officials today announced contracts totaling $132.5 million to help three companies develop dose-sparing substances, or adjuvants, to be used with H5N1 flu vaccines.
TORONTO (CIDRAP News) The continuing debate over developing countries' ability to afford pandemic-influenza vaccines has produced a disturbing complication: the possibility that Indonesia and other countries affected by H5N1 avian flu will assert legal ownership of the viral isolates on which the vaccines would be based.
Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.